Agricultural pests evolve quickly, rendering conventional chemical treatments obsolete while broad-spectrum applications inflict heavy collateral damage on pollinators. Molagri, a Toronto-based biotechnology startup founded out of the University of Toronto, has raised $5.8 million USD ($8.2 million CAD) in combined pre-seed and seed funding to engineer adaptable, targeted biopesticides designed to spare beneficial species.
According to BetaKit, the startup graduated from Y Combinator's Summer 2026 cohort and closed a seed round led by Convective Capital, with participation from Superorganism, Robinhood Ventures, Julian Capital, and Paul Graham. FinSMEs reported that the capital will finance laboratory expansion in Toronto, field trials, and the recruitment of scientists across molecular biology, virology, and bioassay disciplines.
Targeted Delivery Using Virus-Like Particles
Molagri develops precision biopesticides based on non-infectious, engineered virus-like particles (VLPs). As reported by Agroempresario, these delivery vehicles are engineered to be ingested by specific agricultural pests. Surface proteins on the particles bind specifically to receptor molecules inside the target insect's digestive tract, avoiding uptake by beneficial pollinators like honeybees.
Once inside target insect cells, the particles release a messenger RNA payload that directs the insect's own cellular machinery to produce an insecticidal protein. Because the platform separates the receptor-binding surface from the internal payload, Molagri can update either module independently. If a pest population develops resistance to a particular payload mechanism, researchers can swap in an alternate payload without redesigning the entire delivery vehicle. Similarly, if pest receptor mutations arise, the company can modify the particle's external targeting proteins.
Molagri plans to manufacture its particles via yeast fermentation, a scalable biomanufacturing route standard in industrial biotech. The company is directing its early development toward tree fruits and tree nuts—such as almonds and pistachios targeted by the navel orangeworm, and apples hit by the codling moth—where orchard crops cannot be easily rotated to disrupt pest life cycles.
Founded by Viral Structural Biologists
Molagri was founded by Zaky Hassan (CEO) and Min Jin (CSO), both protein biochemists and PhD candidates from the University of Toronto who spent six years working together in the same research laboratory. Both founders have published research in Nature Communications and Nature Microbiology examining coronavirus structures and antibody neutralization mechanisms.
Jin holds the world record for the highest-resolution structure of a coronavirus spike protein deposited in the Protein Data Bank (1.68 Å). The founders have turned this structural biology expertise toward agricultural ecology, solving insect receptor structures—including receptors in honeybees via cryo-electron microscopy—to pinpoint molecular differences between crop pests and non-target insects.
In a video interview with Visions of Science, Hassan described his path into biochemistry research and his earlier work running community youth programming in Toronto. Speaking to The Globe and Mail, Hassan noted that while commercial products remain several years away due to formulation and regulatory evaluation, creating modular biopesticides offers a path to outpace pest mutation without resorting to heavier chemical spraying.
Scientific Hiring in Toronto
Molagri operates out of a laboratory facility in Toronto equipped for tissue culture and biomanufacturing. To advance candidates from design to field validation, the company is doubling its four-person team with four senior hires across its core technical workflows.
To build delivery systems, Molagri is hiring a Scientist / Senior Scientist, Synthetic Virology for RNA Delivery ($130,000–$160,000 CAD) to engineer non-replicative VLP systems that package and deliver programmable RNA payloads, developing design-build-test loops and QC assays for packaging efficiency. For surface engineering, the team is recruiting a Scientist / Senior Scientist, Molecular Display and Binder Discovery ($130,000–$160,000 CAD) to stand up phage and yeast-display workflows, managing the process from cloning pooled oligo libraries to binder hit validation against insect receptors.
Downstream, a Scientist / Senior Scientist, Insect Biology and Bioassays ($130,000–$160,000 CAD) will establish insect-cell assays and whole-insect bioassays to test whether VLPs successfully enter tissue, deliver RNA payloads, and drive insecticidal activity. Supporting production, a Sr. Research Associate, Yeast Expression and VLP Production ($85,000–$105,000 CAD) will produce engineered particles in yeast, running purification, stability, and quality control pipelines to generate material for insect screening.
All four positions are onsite roles based in Toronto.
Open Roles at Molagri
| Role | Location | Work Mode | Salary |
|---|---|---|---|
| Scientist / Senior Scientist, Molecular Display and Binder Discovery | Toronto, ON, CA | Onsite | $130,000 – $160,000 CAD |
| Scientist / Senior Scientist, Insect Biology and Bioassays | Toronto, ON, CA | Onsite | $130,000 – $160,000 CAD |
| Scientist / Senior Scientist, Synthetic Virology for RNA Delivery | Toronto, ON, CA | Onsite | $130,000 – $160,000 CAD |
| Sr. Research Associate, Yeast Expression and VLP Production | Toronto, ON, CA | Onsite | $85,000 – $105,000 CAD |





